Texas Permanent School Fund increased its stake in Inogen, Inc. (NASDAQ:INGN – Get Rating) by 10.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,364 shares of the medical technology company’s stock after purchasing an additional 1,602 shares during the period. Texas Permanent School Fund owned 0.07% of Inogen worth $397,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently bought and sold shares of the stock. Legal & General Group Plc boosted its stake in Inogen by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 57,104 shares of the medical technology company’s stock worth $1,380,000 after purchasing an additional 434 shares in the last quarter. Mutual of America Capital Management LLC lifted its stake in Inogen by 17.2% during the 2nd quarter. Mutual of America Capital Management LLC now owns 3,452 shares of the medical technology company’s stock valued at $83,000 after acquiring an additional 506 shares during the period. Captrust Financial Advisors lifted its stake in Inogen by 124.7% during the 1st quarter. Captrust Financial Advisors now owns 993 shares of the medical technology company’s stock valued at $32,000 after acquiring an additional 551 shares during the period. US Bancorp DE lifted its stake in Inogen by 273.0% during the 1st quarter. US Bancorp DE now owns 884 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 647 shares during the period. Finally, American International Group Inc. lifted its stake in Inogen by 7.6% during the 2nd quarter. American International Group Inc. now owns 12,276 shares of the medical technology company’s stock valued at $297,000 after acquiring an additional 869 shares during the period. 95.93% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several analysts have commented on the stock. Needham & Company LLC decreased their price objective on shares of Inogen from $45.00 to $36.00 and set a “buy” rating for the company in a research note on Wednesday, November 2nd. JPMorgan Chase & Co. cut their target price on shares of Inogen from $32.00 to $22.00 and set a “neutral” rating for the company in a report on Thursday, November 3rd. Finally, StockNews.com began coverage on shares of Inogen in a report on Wednesday, October 12th. They set a “hold” rating for the company.
Inogen Price Performance
Inogen (NASDAQ:INGN – Get Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The medical technology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.23. The business had revenue of $105.39 million for the quarter, compared to analysts’ expectations of $97.57 million. Inogen had a negative net margin of 13.69% and a negative return on equity of 11.02%. As a group, analysts anticipate that Inogen, Inc. will post -1.88 EPS for the current year.
Inogen Company Profile
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
- Get a free copy of the StockNews.com research report on Inogen (INGN)
- General Electric Stock, The Sum of All Parts Strategy is Paying Off
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.